Publications
115
Citations
2,465
Est. group size
~20
Recurring co-author estimate
Active years
30
Publishing since 1997
Typically publishes in teams of ~20 · 8% small-team papers (≤3 authors) · across 16 venues
- A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Blood Cancer Discovery · 2026
- Dysregulated HELLS expression alters cellular processes and serves as a potential prognostic marker in acute myeloid leukemia
Journal of Biological Chemistry · 2026
- 138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
Hematological Oncology · 2025
- Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update
Blood · 2025
- IBCL-1066: ELARA Phase 2 Clinical Outcomes for Tisagenlecleucel in Patients With High-Risk Relapsed/Refractory Follicular Lymphoma: 4-Year Update
Clinical Lymphoma Myeloma & Leukemia · 2025
- POSTER: IBCL-1066 ELARA Phase 2 Clinical Outcomes for Tisagenlecleucel in Patients With High-Risk Relapsed/Refractory Follicular Lymphoma: 4-Year Update
Clinical Lymphoma Myeloma & Leukemia · 2025
- Maintaining a High Electronic Quality Surface During Patterned Plasma Etching Processes for HJT-IBC Solar Cells
2025
- Quality of Work Life and Employee Performance: A Study of Indian Railway Employees
Journal of Emerging Technologies and Innovative Research · 2025
- Mechanistic basis of the acute safety profile of rese-cel, an autologous CD19-CAR T, in patients with autoimmune disease treated in four ongoing phase 1/2 clinical trials
Blood · 2025
- Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Blood · 2024
- Innovative cell therapies for systemic sclerosis: available evidence and new perspectives
Expert Review of Clinical Immunology · 2024
- Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up
Transplantation and Cellular Therapy · 2024
- Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
Blood · 2024
- Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
Blood · 2024
- Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)
Blood · 2024
- Blood×28
- Transplantation and Cellular Therapy×13
- Biology of Blood and Marrow Transplantation×10
- Clinical Lymphoma Myeloma & Leukemia×10
- Journal of Clinical Oncology×7
- Audrey M. Sigmund
Medicine · The Ohio State University
- Nathan Denlinger
Medicine · The Ohio State University
- Nirav N. Shah
Medicine · University of Michigan
- Khushali Jhaveri
Medicine · Indiana University
- Jang Hwan Cho
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile